New research in JHEP Reports explores how Salsalate, a rheumatoid arthritis therapy, may enhance the effectiveness of Lenvatinib in treating MASH-driven hepatocellular carcinoma (HCC). By stimulating AMPK, enhancing fatty acid oxidation, and reducing steatosis, fibrosis, and tumor proliferation, Salsalate helps create a more favorable liver microenvironment, potentially improving treatment outcomes.
Findings suggest that combining Salsalate with Lenvatinib leads to better tumor suppression, reduced angiogenesis, and prolonged survival in preclinical models. These effects are associated with AMPK activation and inhibition of mTOR-HIF1α and Erk1/2 signaling pathways, opening the door for a promising therapeutic approach in MASH-associated HCC.
For more details, check out the full study: https://lnkd.in/evDuvb47
